MF-300 sarcopenia program
phase 2drug program · high · Fri Dec 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop an oral small-molecule therapy targeting PGE-2 signaling for sarcopenia, aiming to restore tissue homeostasis and improve age-related muscle decline.
Phase 2b clinical study of MF-300; separate healthy-participant single-ascending-dose, food-effect, and multiple-ascending-dose evaluation in non-elderly and elderly adults.
Phase 2b study for sarcopenia; ClinicalTrials.gov record for single and multiple ascending dosing of MF-300 published 2024-12-20.